 <h1>Pamidronate Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of pamidronate include:</b> urinary tract infection, cough, dyspepsia, dyspnea, myalgia, abdominal pain, anemia, anxiety, constipation, diarrhea, fatigue, fever, hypervolemia, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, infusion site reaction, insomnia, nausea, ostealgia, pain, thrombocytopenia, vomiting, and anorexia. <b>Other side effects include:</b> atrial fibrillation, candidiasis, psychosis, syncope, uremia, drowsiness, gastrointestinal hemorrhage, hypertension, hypothyroidism, leukopenia, rales, rhinitis, and tachycardia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pamidronate: intravenous powder for solution, intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pamidronate may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking pamidronate:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach cramps</li>
<li>black, tarry stools</li>
<li>bloody in the urine or stools</li>
<li>blurred vision</li>
<li>chest pain</li>
<li>chills</li>
<li>confusion</li>
<li>convulsions (seizures)</li>
<li>decrease in the amount of urine</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>fainting</li>
<li>fast or irregular heartbeat</li>
<li>fever</li>
<li>headache</li>
<li>increased thirst</li>
<li>loss of appetite</li>
<li>muscle pain, cramps, spasms, or twitching</li>
<li>nausea or vomiting</li>
<li>nervousness</li>
<li>noisy, rattling breathing</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>shortness of breath</li>
<li>slow or fast heartbeat</li>
<li>swelling of the fingers, hands, feet, or lower legs</li>
<li>trembling</li>
<li>troubled breathing at rest</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
<li>weight gain</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Cough</li>
<li>dilated neck veins</li>
<li>extreme fatigue</li>
<li>irregular breathing</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>swelling</li>
<li>ulcers, sores, or white spots in the mouth</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Decreased vision</li>
<li>difficulty with swallowing</li>
<li>eye pain or tenderness</li>
<li>eye redness</li>
<li>hives</li>
<li>itching</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>sensitivity of the eye to light</li>
<li>skin rash</li>
<li>sweating</li>
<li>tearing of the eye</li>
<li>tightness in the chest</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bone, joint, or muscle pain, severe and occasionally incapacitating</li>
<li>faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of pamidronate may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>bladder pain</li>
<li>bloody or cloudy urine</li>
<li>body aches or pain</li>
<li>bone pain</li>
<li>constipation</li>
<li>cracks in the skin at the corners of mouth</li>
<li>diarrhea</li>
<li>difficult, burning, or painful urination</li>
<li>difficult or labored breathing</li>
<li>difficulty moving</li>
<li>ear congestion</li>
<li>fear</li>
<li>frequent urge to urinate</li>
<li>heartburn</li>
<li>indigestion</li>
<li>joint pain</li>
<li>lack or loss of strength</li>
<li>lower back or side pain</li>
<li>muscle aching, cramping, pains, or stiffness</li>
<li>nasal congestion</li>
<li>nervousness</li>
<li>pain and swelling at the injection site</li>
<li>sensitivity to heat</li>
<li>shivering</li>
<li>sneezing</li>
<li>soreness or redness around the fingernails and toenails</li>
<li>stomach discomfort, upset, or pain</li>
<li>sweating</li>
<li>swollen joints</li>
<li>trouble sleeping</li>
<li>weight loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Ammonia-like breath odor</li>
<li>feeling, seeing, or hearing things that are not there</li>
<li>feeling that others are watching you or controlling your behavior</li>
<li>feeling that others can hear your thoughts</li>
<li>feeling unusually cold</li>
<li>swelling or inflammation of the mouth</li>
<li>unusual behavior</li>
</ul><p>
<!-- end intravenous powder for solution, intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pamidronate: intravenous powder for injection, intravenous solution</i></p><h3>General</h3><p>This drug has been generally well tolerated and many adverse effects that occurred during treatment may have been related to the underlying disease state.  Adverse effects have been most often associated with larger (90 mg) doses of pamidronate.  The most common adverse effect has been fever, occurring in up to 41% of patients.  The fever was generally mild and transient.  Onset was typically within the first 48 hours after infusion and resolution was within another 48 hours.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, vomiting, abdominal pain, diarrhea, constipation, gastritis, dyspepsia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (15%)</p>
<p><b>Common</b> (1% to 10%): Moniliasis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypocalcemia, hypophosphatemia, anorexia, fluid overload</p>
<p><b>Common</b> (1% to 10%): Hypokalemia, hypomagnesemia</p>
<p><b>Very rare</b> (less than 0.01%): Hyperkalemia, hypernatremia<sup>[Ref]</sup></p><p>Presentation of hypocalcemia may be delayed.  In one case report, the patient presented with fingertip paresthesias and a serum calcium of 6.8 mEq/L (7.8 mEq/mL, corrected) 13 days after a single infusion of pamidronate.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthrosis</p>
<p><b>Common</b> (1% to 10%): Transient bone pain, arthralgia, myalgia, generalized pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Muscle cramps, osteonecrosis</p>
<p><b>Postmarketing reports</b>: Atypical subtrochanteric and diaphyseal femoral fractures<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever and influenza-like symptoms sometimes accompanied by malaise, rigor, fatigue, flushes, asthenia</p>
<p><b>Very rare</b> (less than 0.01%): Reactivation of Herpes simplex, reactivation of Herpes zoster<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very rare</b> (less than 0.01%): Acute respiratory distress syndrome, interstitial lung disease</p>
<p><b>Postmarketing reports</b>: Adult respiratory distress syndrome (ARDS), interstitial lung disease (ILD)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Atrial fibrillation, hypertension</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypotension</p>
<p><b>Very rare</b> (less than 0.01%): Left ventricular failure (dyspnea, pulmonary edema), congestive heart failure (edema) due to fluid overload<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Pruritus<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Leukopenia was generally mild and transient.  In one study, granulocytopenia occurred in 4.2% of patients but completely resolved after discontinuation of pamidronate therapy.  Patients with anemia, leukopenia, or thrombocytopenia prior to initiation of pamidronate should be carefully monitored during the first 2 weeks of therapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Anemia, thrombocytopenia, lymphocytopenia, leukopenia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Reactions at the infusion site (pain, redness, swelling, induration, phlebitis, thrombophlebitis)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Symptomatic hypocalcemia (tetany, paresthesia), headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Seizures, lethargy, dizziness</p>
<p><b>Very rare</b> (less than 0.01%): Confusion<sup>[Ref]</sup></p><h3>Ocular</h3><p>Uveitis generally occurs within 24 to 48 hours after administration of pamidronate.  The uveitis may be bilateral, and reversible, partial 3rd and 4th nerve palsies have been reported with the uveitis.  Recurrences have occurred with rechallenge of the drug.  Therapy with pamidronate should be discontinued if uveitis occurs.  Although severe cases have been reported, most symptoms have resolved on discontinuation of pamidronate with minimal or no intervention.</p>
<p></p>
<p>A nonspecific conjunctivitis has been reported with pamidronate use. The conjunctivitis may consist of any or all of the following symptoms: conjunctival hyperemia, irritation, epiphora, discharge, and blurred vision. These symptoms may appear within the first 6 to 48 hours after administration of the drug and generally resolve within a few days after drug discontinuation.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Conjunctivitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Uveitis (iritis, iridocyclitis)</p>
<p><b>Very rare</b> (less than 0.01%): Scleritis, episcleritis, xanthopsia</p>
<p><b>Frequency not reported</b>: Optic neuritis</p>
<p><b>Postmarketing reports</b>: Orbital inflammation<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p>
<p><b>Uncommon</b> (0.1% to 1%): Agitation</p>
<p><b>Very rare</b> (less than 0.01%): Visual hallucinations<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increase in serum creatinine</p>
<p><b>Uncommon</b> (0.1% to 1%): Increase in serum urea, acute renal failure</p>
<p><b>Rare</b> (0.01% to 0.1%): Focal segmental glomerulosclerosis including the collapsing variant, nephrotic syndrome</p>
<p><b>Very rare</b> (less than 0.01%): Deterioration of pre-existing renal disease, hematuria, renal tubular disorder, tubulointerstitial nephritis, glomerulonephropathy<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hypothyroidism in patients receiving doses of 90 mg<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal liver function test<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Allergic reactions including anaphylactoid reactions, bronchospasm/dyspnea, Quincke's (angioneurotic) edema</p>
<p><b>Very rare</b> (less than 0.01%): Anaphylactic shock<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Aredia (pamidronate)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_4">4. "Product Information. Pamidronate Disodium (pamidronate)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_5">5. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89</p><p id="ref_6">6. Gallacher SJ, Ralston SH, Patel U, Boyle IT "Side-effects of pamidronate." Lancet 2 (1989): 42-3</p><p id="ref_7">7. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE "A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy." Br J Cancer 72 (1995): 1289-93</p><p id="ref_8">8. Spivacow FR, Zanchetta JR, Kerzberg EM, Frigeri A, Fiasche R, Roldan EJA "Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases." Curr Ther Res Clin Exp 57 (1996): 123-30</p><p id="ref_9">9. Mautalen CA, Casco CA, Gonzalez D, Ghiringhelli GR, Massironi C, Fromm GA, Plantalech L "Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases." Br Med J (Clin Res Ed) 288 (1984): 828-9</p><p id="ref_10">10. Herrera JA, Sarabia MO, Gonzalez MM "Effects of treatment with bisphosphonates on gastrointestinal and esophageal mucosa in patients with osteoporosis: Pamidronate versus alendronate." Curr Ther Res Clin Exp 60 (1999): 307-13</p><p id="ref_11">11. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, "Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial." J Clin Oncol 17 (1999): 846-54</p><p id="ref_12">12. Jodrell DI, Iveson TJ, Smith IE "Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate." Lancet 1 (1987): 622</p><p id="ref_13">13. Palmieri C,  Dhillon T,  Coombes C,  Vigushin D "Hypocalcaemia after intravenous bisphosphonate: adjuvant bisphosphonate is not currently accepted practice." BMJ 328 (2004): 1439; author reply 1439-40</p><p id="ref_14">14. Rosen CJ,  Brown S "Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency." N Engl J Med 348 (2003): 1503-4</p><p id="ref_15">15. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ "Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases - Long term follow-up of two randomized, placebo-controlled trials." Cancer 88 (2000): 1082-90</p><p id="ref_16">16. Malnick SD, Ariel-Ronen S, Evron E, Sthoeger ZM "Acute pseudogout as a complication of pamidronate." Ann Pharmacother 31 (1997): 499-500</p><p id="ref_17">17. Reid IR, Cundy T, Ibbertson HK, King AR "Osteomalacia after pamidronate for pagets disease." Lancet 343 (1994): 855</p><p id="ref_18">18. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF "Mineralisation defects with pamidronate therapy for paget's disease." Lancet 342 (1993): 1459-60</p><p id="ref_19">19. Kellihan MJ, Mangino PD "Pamidronate." Ann Pharmacother 26 (1992): 1262-9</p><p id="ref_20">20. Bamias A,  Kastritis E,  Bamia C, et al. "Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors." J Clin Oncol 23 (2005): 8580-7</p><p id="ref_21">21. Liens D, Delmas PD, Meunier PJ "Long-term effects of intravenous pamidronate in fibrous dysplasia of bone." Lancet 343 (1994): 953-4</p><p id="ref_22">22. Foley-Nolan D, Daly MJ, Williams D, Wasti A, Martin M "Pamidronate associated hallucinations." Ann Rheum Dis 51 (1992): 927-8</p><p id="ref_23">23. Macarol V, Fraunfelder FT "Pamidronate disodium and possible ocular adverse drug reactions." Am J Ophthalmol 118 (1994): 220-4</p><p id="ref_24">24. De S, Meyer P, Crisp AJ "Pamidronate and uveitis." Br J Rheumatol 34 (1995): 479</p><p id="ref_25">25. Odonnell NP, Rao GP, Aguisfernandez A "Paget's disease: ocular complications of disodium pamidronate treatment." Br J Clin Pract 49 (1995): 272-3</p><p id="ref_26">26. Stewart GO, Stuckey BGA, Ward LC, Prince RL, Gutteridge DH, Constable IJ "Iritis following intravenous pamidronate." Aust N Z J Med 26 (1996): 414-5</p><p id="ref_27">27. Ghose K, Waterworth R, Trolove P, Highton J "Uveitis associated with pamidronate." Aust N Z J Med 24 (1994): 320</p><p id="ref_28">28. Machado CE, Flombaum CD "Safety of pamidronate in patients with renal failure and hypercalcemia." Clin Nephrol 45 (1996): 175-9</p></div>
<div class="more-resources" id="moreResources">
<h2>More about pamidronate</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: bisphosphonates</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pamidronate Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Aredia</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hypercalcemia</li>
<li>Hypercalcemia of Malignancy</li>
<li>Paget's Disease</li>
<li>Breast Cancer, Bone Metastases</li>
<li>Osteolytic Bone Lesions of Multiple Myeloma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pamidronate: intravenous powder for injection, intravenous solution</i></p><h3>General</h3><p>This drug has been generally well tolerated and many adverse effects that occurred during treatment may have been related to the underlying disease state.  Adverse effects have been most often associated with larger (90 mg) doses of pamidronate.  The most common adverse effect has been fever, occurring in up to 41% of patients.  The fever was generally mild and transient.  Onset was typically within the first 48 hours after infusion and resolution was within another 48 hours.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea, vomiting, abdominal pain, diarrhea, constipation, gastritis, dyspepsia<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (15%)</p><p><b>Common</b> (1% to 10%): Moniliasis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypocalcemia, hypophosphatemia, anorexia, fluid overload</p><p><b>Common</b> (1% to 10%): Hypokalemia, hypomagnesemia</p><p><b>Very rare</b> (less than 0.01%): Hyperkalemia, hypernatremia<sup>[Ref]</sup></p><p>Presentation of hypocalcemia may be delayed.  In one case report, the patient presented with fingertip paresthesias and a serum calcium of 6.8 mEq/L (7.8 mEq/mL, corrected) 13 days after a single infusion of pamidronate.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthrosis</p><p><b>Common</b> (1% to 10%): Transient bone pain, arthralgia, myalgia, generalized pain</p><p><b>Uncommon</b> (0.1% to 1%): Muscle cramps, osteonecrosis</p><p><b>Postmarketing reports</b>: Atypical subtrochanteric and diaphyseal femoral fractures<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever and influenza-like symptoms sometimes accompanied by malaise, rigor, fatigue, flushes, asthenia</p><p><b>Very rare</b> (less than 0.01%): Reactivation of Herpes simplex, reactivation of Herpes zoster<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very rare</b> (less than 0.01%): Acute respiratory distress syndrome, interstitial lung disease</p><p><b>Postmarketing reports</b>: Adult respiratory distress syndrome (ARDS), interstitial lung disease (ILD)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Atrial fibrillation, hypertension</p><p><b>Uncommon</b> (0.1% to 1%): Hypotension</p><p><b>Very rare</b> (less than 0.01%): Left ventricular failure (dyspnea, pulmonary edema), congestive heart failure (edema) due to fluid overload<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Uncommon</b> (0.1% to 1%): Pruritus<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Leukopenia was generally mild and transient.  In one study, granulocytopenia occurred in 4.2% of patients but completely resolved after discontinuation of pamidronate therapy.  Patients with anemia, leukopenia, or thrombocytopenia prior to initiation of pamidronate should be carefully monitored during the first 2 weeks of therapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Anemia, thrombocytopenia, lymphocytopenia, leukopenia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Reactions at the infusion site (pain, redness, swelling, induration, phlebitis, thrombophlebitis)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Symptomatic hypocalcemia (tetany, paresthesia), headache</p><p><b>Uncommon</b> (0.1% to 1%): Seizures, lethargy, dizziness</p><p><b>Very rare</b> (less than 0.01%): Confusion<sup>[Ref]</sup></p><h3>Ocular</h3><p>Uveitis generally occurs within 24 to 48 hours after administration of pamidronate.  The uveitis may be bilateral, and reversible, partial 3rd and 4th nerve palsies have been reported with the uveitis.  Recurrences have occurred with rechallenge of the drug.  Therapy with pamidronate should be discontinued if uveitis occurs.  Although severe cases have been reported, most symptoms have resolved on discontinuation of pamidronate with minimal or no intervention.</p><p></p><p>A nonspecific conjunctivitis has been reported with pamidronate use. The conjunctivitis may consist of any or all of the following symptoms: conjunctival hyperemia, irritation, epiphora, discharge, and blurred vision. These symptoms may appear within the first 6 to 48 hours after administration of the drug and generally resolve within a few days after drug discontinuation.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Conjunctivitis</p><p><b>Uncommon</b> (0.1% to 1%): Uveitis (iritis, iridocyclitis)</p><p><b>Very rare</b> (less than 0.01%): Scleritis, episcleritis, xanthopsia</p><p><b>Frequency not reported</b>: Optic neuritis</p><p><b>Postmarketing reports</b>: Orbital inflammation<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Insomnia</p><p><b>Uncommon</b> (0.1% to 1%): Agitation</p><p><b>Very rare</b> (less than 0.01%): Visual hallucinations<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increase in serum creatinine</p><p><b>Uncommon</b> (0.1% to 1%): Increase in serum urea, acute renal failure</p><p><b>Rare</b> (0.01% to 0.1%): Focal segmental glomerulosclerosis including the collapsing variant, nephrotic syndrome</p><p><b>Very rare</b> (less than 0.01%): Deterioration of pre-existing renal disease, hematuria, renal tubular disorder, tubulointerstitial nephritis, glomerulonephropathy<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Hypothyroidism in patients receiving doses of 90 mg<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Abnormal liver function test<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Allergic reactions including anaphylactoid reactions, bronchospasm/dyspnea, Quincke's (angioneurotic) edema</p><p><b>Very rare</b> (less than 0.01%): Anaphylactic shock<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Aredia (pamidronate)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_4">4. "Product Information. Pamidronate Disodium (pamidronate)." Teva Pharmaceuticals USA, North Wales, PA. </p><p id="ref_5">5. Lourwood DL "The pharmacology and therapeutic utility of bisphosphonates." Pharmacotherapy 18 (1998): 779-89</p><p id="ref_6">6. Gallacher SJ, Ralston SH, Patel U, Boyle IT "Side-effects of pamidronate." Lancet 2 (1989): 42-3</p><p id="ref_7">7. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE "A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy." Br J Cancer 72 (1995): 1289-93</p><p id="ref_8">8. Spivacow FR, Zanchetta JR, Kerzberg EM, Frigeri A, Fiasche R, Roldan EJA "Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases." Curr Ther Res Clin Exp 57 (1996): 123-30</p><p id="ref_9">9. Mautalen CA, Casco CA, Gonzalez D, Ghiringhelli GR, Massironi C, Fromm GA, Plantalech L "Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases." Br Med J (Clin Res Ed) 288 (1984): 828-9</p><p id="ref_10">10. Herrera JA, Sarabia MO, Gonzalez MM "Effects of treatment with bisphosphonates on gastrointestinal and esophageal mucosa in patients with osteoporosis: Pamidronate versus alendronate." Curr Ther Res Clin Exp 60 (1999): 307-13</p><p id="ref_11">11. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, "Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial." J Clin Oncol 17 (1999): 846-54</p><p id="ref_12">12. Jodrell DI, Iveson TJ, Smith IE "Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate." Lancet 1 (1987): 622</p><p id="ref_13">13. Palmieri C,  Dhillon T,  Coombes C,  Vigushin D "Hypocalcaemia after intravenous bisphosphonate: adjuvant bisphosphonate is not currently accepted practice." BMJ 328 (2004): 1439; author reply 1439-40</p><p id="ref_14">14. Rosen CJ,  Brown S "Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency." N Engl J Med 348 (2003): 1503-4</p><p id="ref_15">15. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ "Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases - Long term follow-up of two randomized, placebo-controlled trials." Cancer 88 (2000): 1082-90</p><p id="ref_16">16. Malnick SD, Ariel-Ronen S, Evron E, Sthoeger ZM "Acute pseudogout as a complication of pamidronate." Ann Pharmacother 31 (1997): 499-500</p><p id="ref_17">17. Reid IR, Cundy T, Ibbertson HK, King AR "Osteomalacia after pamidronate for pagets disease." Lancet 343 (1994): 855</p><p id="ref_18">18. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF "Mineralisation defects with pamidronate therapy for paget's disease." Lancet 342 (1993): 1459-60</p><p id="ref_19">19. Kellihan MJ, Mangino PD "Pamidronate." Ann Pharmacother 26 (1992): 1262-9</p><p id="ref_20">20. Bamias A,  Kastritis E,  Bamia C, et al. "Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors." J Clin Oncol 23 (2005): 8580-7</p><p id="ref_21">21. Liens D, Delmas PD, Meunier PJ "Long-term effects of intravenous pamidronate in fibrous dysplasia of bone." Lancet 343 (1994): 953-4</p><p id="ref_22">22. Foley-Nolan D, Daly MJ, Williams D, Wasti A, Martin M "Pamidronate associated hallucinations." Ann Rheum Dis 51 (1992): 927-8</p><p id="ref_23">23. Macarol V, Fraunfelder FT "Pamidronate disodium and possible ocular adverse drug reactions." Am J Ophthalmol 118 (1994): 220-4</p><p id="ref_24">24. De S, Meyer P, Crisp AJ "Pamidronate and uveitis." Br J Rheumatol 34 (1995): 479</p><p id="ref_25">25. Odonnell NP, Rao GP, Aguisfernandez A "Paget's disease: ocular complications of disodium pamidronate treatment." Br J Clin Pract 49 (1995): 272-3</p><p id="ref_26">26. Stewart GO, Stuckey BGA, Ward LC, Prince RL, Gutteridge DH, Constable IJ "Iritis following intravenous pamidronate." Aust N Z J Med 26 (1996): 414-5</p><p id="ref_27">27. Ghose K, Waterworth R, Trolove P, Highton J "Uveitis associated with pamidronate." Aust N Z J Med 24 (1994): 320</p><p id="ref_28">28. Machado CE, Flombaum CD "Safety of pamidronate in patients with renal failure and hypercalcemia." Clin Nephrol 45 (1996): 175-9</p><h2>More about pamidronate</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: bisphosphonates</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pamidronate Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +3 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hypercalcemia</li>
<li>Hypercalcemia of Malignancy</li>
<li>Paget's Disease</li>
<li>Breast Cancer, Bone Metastases</li>
<li>Osteolytic Bone Lesions of Multiple Myeloma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>